PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19557637-4 2009 We investigated the effect of rapamycin on both P-gp function and the MDR phenotype in four cell lines. Sirolimus 30-39 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 18594053-5 2008 DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus. Sirolimus 191-200 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 19728747-14 2009 Proliferation signal inhibitors (PSIs) such as sirolimus and everolimus are substrates of CYP3A4 and P-glycoprotein and have a macrolide structure very similar to tacrolimus, which explains why common drug interactions with PSIs are comparable to those with calcineurin inhibitors. Sirolimus 47-56 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 18594053-5 2008 DATA SYNTHESIS: Corticosteroids share common metabolic and transporter pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1) systems, respectively, with cyclosporine, tacrolimus, and sirolimus. Sirolimus 191-200 ATP binding cassette subfamily B member 1 Homo sapiens 126-131 17912526-13 2008 CONCLUSION: Our results show that rapamycin displays antiproliferative effects and induces apoptosis in HNSCC cell lines, cellular effects being more potent in cells that do not express BCL2 and MDR1. Sirolimus 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 195-199 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Sirolimus 107-116 ATP binding cassette subfamily B member 1 Homo sapiens 174-188 17941052-0 2008 Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Sirolimus 62-71 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 17889118-3 2007 The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes. Sirolimus 136-145 ATP binding cassette subfamily B member 1 Homo sapiens 228-242 17889118-3 2007 The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes. Sirolimus 136-145 ATP binding cassette subfamily B member 1 Homo sapiens 263-285 17889118-3 2007 The purpose of this study was to provide a short overview of recent results obtained in the field of pharmacogenetics of tacrolimus and sirolimus, both substrates of the cytochrome P450 3A (CYP3A) enzymes and of the efflux pump P-glycoprotein, the product of the Multidrug Resistance-1 (MDR1) genes. Sirolimus 136-145 ATP binding cassette subfamily B member 1 Homo sapiens 287-291 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Sirolimus 107-116 ATP binding cassette subfamily B member 1 Homo sapiens 190-193 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Sirolimus 107-116 ATP binding cassette subfamily B member 1 Homo sapiens 195-200 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Sirolimus 107-116 ATP binding cassette subfamily B member 1 Homo sapiens 203-233 17031644-1 2007 PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP). Sirolimus 107-116 ATP binding cassette subfamily B member 1 Homo sapiens 235-240 17031644-7 2007 Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 microM, but was effective at its clinically achievable concentration of 0.25 microM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 microM. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 64-67 17031644-7 2007 Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 microM, but was effective at its clinically achievable concentration of 0.25 microM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 microM. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 17031644-9 2007 CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations. Sirolimus 33-42 ATP binding cassette subfamily B member 1 Homo sapiens 70-73 17031644-9 2007 CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations. Sirolimus 33-42 ATP binding cassette subfamily B member 1 Homo sapiens 75-80 16837925-0 2006 Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Sirolimus 72-81 ATP binding cassette subfamily B member 1 Homo sapiens 8-22 16837925-2 2006 Cyclosporine and sirolimus are P-glycoprotein (Pgp) substrates. Sirolimus 17-26 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 16837925-2 2006 Cyclosporine and sirolimus are P-glycoprotein (Pgp) substrates. Sirolimus 17-26 ATP binding cassette subfamily B member 1 Homo sapiens 47-50 16911499-15 2006 Sirolimus is also a substrate of p-glycoprotein and thus may be significantly affected by amiodarone. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 33-47 16249748-0 2005 Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 16837925-3 2006 We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus. Sirolimus 219-228 ATP binding cassette subfamily B member 1 Homo sapiens 25-28 16837925-3 2006 We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus. Sirolimus 307-316 ATP binding cassette subfamily B member 1 Homo sapiens 25-28 16837925-8 2006 Pgp expression and function were confirmed in HRECs and cyclosporine and sirolimus were shown to be Pgp inhibitors in this model. Sirolimus 73-82 ATP binding cassette subfamily B member 1 Homo sapiens 100-103 16837925-13 2006 The inhibitory effect of sirolimus on Pgp-mediated efflux and the cellular concentration of cyclosporine could explain the exacerbation of cyclosporine nephrotoxicity observed clinically. Sirolimus 25-34 ATP binding cassette subfamily B member 1 Homo sapiens 38-41 16249748-7 2005 CYP3A5 (intron 3) and MDR1 (exons 12, 21, 26) genotypes were correlated to the adjusted trough concentrations and dose requirements for both sirolimus and tacrolimus. Sirolimus 141-150 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 15760093-8 2004 Sirolimus is a substrate for both Cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp) and undergoes extensive first-pass extraction. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 15686733-1 2004 Sirolimus, a new immunosuppressant drug; is metabolized by cytochrome P450 3A4 (CYP3A4) and is a substrate of the P-glycoprotein drug efflux pump. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 15707415-1 2005 Sirolimus (SRL) is a substrate for cytochromes P-450 3A and P-glycoprotein, the product of the MDR1 gene. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 15707415-3 2005 We then evaluated in 149 renal transplant recipients the effect of polymorphisms CYP3A4*1/*1B, CYP3A5*1/*3 and MDR1 SNPs in exon 12, 21 and 26 on SRL concentration/dose (C/D) ratio 3 months after sirolimus introduction. Sirolimus 146-149 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 15760093-8 2004 Sirolimus is a substrate for both Cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp) and undergoes extensive first-pass extraction. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 12235265-8 2002 The interaction of sirolimus with P-glycoprotein was also evaluated in vitro using HCT-8 and Caco-2 cell monolayers. Sirolimus 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 15307840-0 2004 CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Sirolimus 113-122 ATP binding cassette subfamily B member 1 Homo sapiens 11-25 15307840-1 2004 This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients. Sirolimus 131-140 ATP binding cassette subfamily B member 1 Homo sapiens 236-250 15307840-1 2004 This study aimed to determine the impact of maintenance immunosuppressive therapy with cyclosporin A (CsA), tacrolimus (FK506) and sirolimus (Rapa) on the in vivo activity of both intestinal and hepatic cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (PGP) in renal transplant patients. Sirolimus 131-140 ATP binding cassette subfamily B member 1 Homo sapiens 252-255 9465841-1 1998 INTRODUCTION: Sirolimus and cyclosporine (INN, ciclosporin) share the same cytochrome P4503A metabolic pathways, and both drugs are substrates for p-glycoprotein countertransport. Sirolimus 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 147-161 11762554-1 2001 Immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids are substrates for the transmembrane multidrug resistance pump P-glycoprotein (P-gp). Sirolimus 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 153-167 11762554-1 2001 Immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids are substrates for the transmembrane multidrug resistance pump P-glycoprotein (P-gp). Sirolimus 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 10516933-4 1999 The objective of this review is to discuss the effects of P-gp modulation on the pharmacokinetics and the pharmacodynamics of immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, and corticosteroids. Sirolimus 185-194 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 31323368-8 2019 Upon also considering the results of Caco-2 cell assay, it could be speculated that the transport of rapamycin in vivo involved active transport as well as P-glycoprotein (P-gp) based efflux. Sirolimus 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 156-170 8702500-12 1996 Our results support the model that immunosuppressants reverse multidrug resistance by competing with other Pgp substrates but reveal that inhibition of FKBP12-dependent Pgp function may also contribute to reversal of multidrug resistance by FK506 and rapamycin. Sirolimus 251-260 ATP binding cassette subfamily B member 1 Homo sapiens 169-172 8668925-2 1996 Rapamycin was compared to cyclosporine A for its ability to inhibit P-glycoprotein on normal human peripheral blood mononuclear cells (PBMC). Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 68-82 8668925-7 1996 P-glycoprotein inhibition of ex vivo lymphocytes with three multi-drug resistant T-cell lines showed susceptibility of P-glycoprotein to rapamycin dependent on the cell type. Sirolimus 137-146 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 8668925-7 1996 P-glycoprotein inhibition of ex vivo lymphocytes with three multi-drug resistant T-cell lines showed susceptibility of P-glycoprotein to rapamycin dependent on the cell type. Sirolimus 137-146 ATP binding cassette subfamily B member 1 Homo sapiens 119-133 8668925-8 1996 Compared to cyclosporine A, the reduced ability of rapamycin to inhibit P-glycoprotein reflects a reduced avidity in its binding to P-glycoprotein and perhaps increased access to the cell interior. Sirolimus 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 8668925-8 1996 Compared to cyclosporine A, the reduced ability of rapamycin to inhibit P-glycoprotein reflects a reduced avidity in its binding to P-glycoprotein and perhaps increased access to the cell interior. Sirolimus 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 8668925-10 1996 The authors speculate that interactions with P-glycoprotein may partially modulate the immunosuppressive effects of rapamycin. Sirolimus 116-125 ATP binding cassette subfamily B member 1 Homo sapiens 45-59 1381629-8 1992 This is supported by the ability of FK506 and rapamycin to directly compete the binding of the photoaffinity analogue 125I-iodoaryl azidoprazosin to the P-glycoprotein. Sirolimus 46-55 ATP binding cassette subfamily B member 1 Homo sapiens 153-167 35629245-8 2022 ABCB1 homozygous polymorphisms were observed with significantly lower time spent in the therapeutic range with cyclosporine and everolimus/sirolimus. Sirolimus 139-148 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 19709321-8 2009 Increased tacrolimus half-life and increased dose interval of sirolimus and tacrolimus were due to CYP3A4/5 and/or P-glycoprotein inhibition by protease inhibitors. Sirolimus 62-71 ATP binding cassette subfamily B member 1 Homo sapiens 115-129 32420174-0 2020 The effect of ABCB1 polymorphism on sirolimus in renal transplant recipients: a meta-analysis. Sirolimus 36-45 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 32420174-1 2020 Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1. Sirolimus 12-21 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 32420174-1 2020 Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1. Sirolimus 12-21 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 32420174-1 2020 Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1. Sirolimus 12-21 ATP binding cassette subfamily B member 1 Homo sapiens 111-116 32420174-1 2020 Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1. Sirolimus 23-26 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 32420174-1 2020 Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1. Sirolimus 23-26 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 32420174-1 2020 Background: Sirolimus (SRL) is an immunosuppressive drug and substrate of the P-glycoprotein (P-GP) encoded by ABCB1. Sirolimus 23-26 ATP binding cassette subfamily B member 1 Homo sapiens 111-116 32420174-2 2020 The relationship between ABCB1 polymorphism and the pharmacokinetics of SRL in different studies were conflicting in renal transplant recipients. Sirolimus 72-75 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 32420174-3 2020 Thus, this meta-analysis aims to investigate the influence of ABCB1 C3435T, C1236T, and G2677T/A polymorphisms on the dose-adjusted trough level (C/D) of SRL in renal transplant recipients. Sirolimus 154-157 ATP binding cassette subfamily B member 1 Homo sapiens 62-67 32420174-15 2020 To achieve target therapeutic concentrations, ABCB1 C1236T homozygous mutant TT genotype will require a higher dose of sirolimus than wild type GG, especially in Caucasian renal transplant recipients. Sirolimus 119-128 ATP binding cassette subfamily B member 1 Homo sapiens 46-51 32420174-16 2020 ABCB1 G2677T/A TT genotype will also need a higher dose of sirolimus genotype. Sirolimus 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 32420174-17 2020 Genotyping of ABCB1 might help to improve the individualization of SRL for renal transplant recipients. Sirolimus 67-70 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 31323368-8 2019 Upon also considering the results of Caco-2 cell assay, it could be speculated that the transport of rapamycin in vivo involved active transport as well as P-glycoprotein (P-gp) based efflux. Sirolimus 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 172-176 28186963-7 2017 In addition, B392 enhanced the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells through inhibition of Akt/mTOR pathway and Mcl-1 protein expression, and also was active in the p-glycoprotein (p-gp)-overexpressing National Cancer Institute/Adriamycin-Resistant cells with little susceptibility to p-gp. Sirolimus 47-56 ATP binding cassette subfamily B member 1 Homo sapiens 213-217 28355970-2 2018 Sirolimus is metabolized by cytochrome P450 3A4 and is a substrate of the P-glycoprotein (P-gp) drug efflux pump. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 74-88 28355970-2 2018 Sirolimus is metabolized by cytochrome P450 3A4 and is a substrate of the P-glycoprotein (P-gp) drug efflux pump. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 29061787-10 2017 Interestingly, the expression of P-gp was synergistically inhibited by combined treatment of U0126 with LY294002 and also inhibited by an mTORC1 inhibitor, rapamycin. Sirolimus 156-165 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 28676933-2 2017 The metabolism of temsirolimus and its active metabolite sirolimus mainly depends on cytochrome P450 3A4/5 (CYP3A4/A5) and the ABCB1 transporter. Sirolimus 21-30 ATP binding cassette subfamily B member 1 Homo sapiens 127-132 28676933-12 2017 Finally, the effect of the ABCB1-rs1128503, ABCB1-rs2032582 and CYP3A5*3 SNPs on sirolimus pharmacokinetics was confirmed. Sirolimus 81-90 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 28676933-12 2017 Finally, the effect of the ABCB1-rs1128503, ABCB1-rs2032582 and CYP3A5*3 SNPs on sirolimus pharmacokinetics was confirmed. Sirolimus 81-90 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 30324134-9 2018 Moreover, administering the drugs via an endothelial cell barrier decreased the expression of P-glycoprotein (an efflux pump that transports bosutinib) in the endothelial cells, indicating that rapamycin and bosutinib cotreatment has considerable potential for ALS treatment. Sirolimus 194-203 ATP binding cassette subfamily B member 1 Homo sapiens 94-108 28186963-7 2017 In addition, B392 enhanced the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells through inhibition of Akt/mTOR pathway and Mcl-1 protein expression, and also was active in the p-glycoprotein (p-gp)-overexpressing National Cancer Institute/Adriamycin-Resistant cells with little susceptibility to p-gp. Sirolimus 47-56 ATP binding cassette subfamily B member 1 Homo sapiens 317-321 26325438-6 2016 For sirolimus, rs2032582 (ABCB1) T-carriers versus non-T-carriers were associated with higher blood levels (P = .01), with similar results for C/D ratio. Sirolimus 4-13 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 28245187-0 2017 Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant. Sirolimus 58-67 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 26036652-2 2016 Rapamycin (RPM) is in the clinical trials for breast cancer treatment, but its P-gp substrate property leads to poor oral bioavailability and efficacy. Sirolimus 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 26036652-2 2016 Rapamycin (RPM) is in the clinical trials for breast cancer treatment, but its P-gp substrate property leads to poor oral bioavailability and efficacy. Sirolimus 11-14 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 26036652-8 2016 This reveals that the uptake of the RPM (P-gp substrate) has been increased in the presence of chemosensitizer. Sirolimus 36-39 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 26924291-15 2016 CONCLUSION: Sirolimus increases the sensitivity of human OS cells to anticancer drugs in vitro by up-regulating miR-34b interacting with PAK1 and ABCB1. Sirolimus 12-21 ATP binding cassette subfamily B member 1 Homo sapiens 146-151 23434829-11 2013 Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates. Sirolimus 127-136 ATP binding cassette subfamily B member 1 Homo sapiens 153-157 24285256-0 2014 ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients. Sirolimus 31-40 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 24285256-9 2014 These results demonstrated that the haplotype of ABCB1 might be a better index for the prediction of sirolimus blood concentration than single SNPs. Sirolimus 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 24285256-10 2014 Genotyping of ABCB1 and CYP3A5 might help to optimize individualized sirolimus treatments for Chinese renal transplant recipients. Sirolimus 69-78 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 26543771-0 2015 CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients. Sirolimus 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 23073467-0 2012 Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. Sirolimus 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 16-21 20220747-2 2010 Adverse pharmacokinetic interactions are hypothesized with sirolimus, which is a substrate of OATP1B1 and OATP1B3 and an inhibitor of ABCB1, OATP1B1, and OATP1B3 but not of ABCC2. Sirolimus 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 134-139 22016125-8 2011 Calcineurin inhibitors (cyclosporine, tacrolimus) and mTOR inhibitors (sirolimus, everolimus) are particularly susceptible to the effects of substances that inhibit or induce cytochrome P450 (CYP) 3A4 and P-glycoprotein. Sirolimus 71-80 ATP binding cassette subfamily B member 1 Homo sapiens 205-219 22094953-0 2011 Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. Sirolimus 83-92 ATP binding cassette subfamily B member 1 Homo sapiens 16-21 20220747-3 2010 However, competition between sirolimus and ezetimibe for ABCB1 and OATP1B1 is not of major clinical relevance, as confirmed in our randomized, controlled, single-dose study in healthy subjects. Sirolimus 29-38 ATP binding cassette subfamily B member 1 Homo sapiens 57-62